IRIS
UCCELLI, ANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 25.993
Totale 25.993
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 25.993
Totale 25.993
Salva come PNG Salva come JPEG
Città #
Genova 19.862
Genoa 3.038
Rapallo 2.878
Vado Ligure 129
Bordighera 86
Totale 25.993
Salva come PNG Salva come JPEG
Nome #
C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. 208
Composite MRI measures and short-term disability in patients with clinically isolated syndrome suggestive of MS 189
Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy 184
Adult stem cells for spinal cord injury: what types and how do they work? 174
Multipotent mesenchymal stromal cells from amniotic fluid: solid perspectives for clinical application. 173
Neuroprotective features of mesenchymal stem cells. 171
Association of melanoma and natalizumab therapy in the Italian MS population: a second case report. 161
Blood-Brain Barrier Alterations in the Cerebral Cortex in Experimental Autoimmune Encephalomyelitis. 159
Immunotherapy for neurological diseases. 155
Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption 153
Multipotent mesenchymal stromal cells for autoimmune diseases: teaching new dogs old tricks. 151
Unveiling the enigma of the CNS as a B-cell fostering environment. 151
Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. 150
Hereditary motor and sensory neuropathy with myelin outfolding: clinical, genetic and neuropathological study of three cases 150
IFN-γ orchestrates mesenchymal stem cell plasticity through the signal transducer and activator of transcription 1 and 3 and mammalian target of rapamycin pathways 150
Antibodies against Epstein-Barr virus and herpesvirus type 6 are associated with the early phases of multiple sclerosis. 150
Mechanisms of the adaptive immune response inside the central nervous system during inflammatory and autoimmune diseases. 148
Investigation of paroxysmal dystonia in a patient with multiple sclerosis: a transcranial magnetic stimulation study. 148
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. 148
Urinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk Stratification. 146
CCL5-glutamate interaction in central nervous system: Early and acute presynaptic defects in EAE mice 146
Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. 146
Retinal nerve fibre layer measurements and optic nerve head analysis in multiple sclerosis patients. 145
Neurorepair with mesenchymal stem cells: hope or hype? 145
Quantitative 3D investigation of Neuronal network in mouse spinal cord model 145
Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. 144
The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study. 144
In vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanoma 142
Immuno-therapeutic potential of haematopoietic and mesenchymal stem cell transplantation in MS. 142
Autologous stem cell transplantation as rescue therapy in malignant forms of multiple sclerosis. 141
Human mesenchymal stem cells target adhesion molecules and receptors involved in T cell extravasation 141
Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. 141
The molecular signature of therapeutic mesenchymal stem cells exposes the architecture of the hematopoietic stem cell niche synapse. 140
17p11.2 duplication is a common finding in sporadic cases of charcot-marie-tooth type 1 138
Nicotinamide Phosphoribosyltransferase (Nampt) Inhibitors As Therapeutics: Rationales, Controversies, Clinical Experience. 138
Relapses after treatment with rituximab in a patient with multiple sclerosis and anti myelin-associated glycoprotein polyneuropathy. 137
Catastrophic NAD(+) Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE 137
Stem cells for multiple sclerosis: promises and reality. 134
Why should mesenchymal stem cells (MSCs) cure autoimmune diseases? 134
Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis. 134
Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. 133
Sirt6 regulates dendritic cell differentiation, maturation, and function 132
Human mesenchymal stem cells promote survival of T cells in a quiescent state. 132
Autologous hematopoietic stem cell transplantation in multiple sclerosis: A phase II trial. 131
Can we switch microglia's phenotype to foster neuroprotection? Focus on multiple sclerosis. 130
Different MRI patterns in MS worsening after stopping fingolimod 130
Alterations of glutamate release in the spinal cord of mice with experimental autoimmune encephalomyelitis 130
Regulation of human mesenchymal stem cell functions by an autocrine loop involving NAD+ release and P2Y11-mediated signaling. 129
Interferon-γ-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. 129
Selective impairments of motor sequence learning in multiple sclerosis patients with minimal disability 128
Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases 127
Effect of radial shock wave therapy on pain and muscle hypertonia: a double-blind study in patients with multiple sclerosis. 127
A restricted T cell response to myelin basic protein (MBP) is stable in multiple sclerosis (MS) patients. 127
Immunological patterns identifying disease course and evolution in multiple sclerosis patients. 127
A major influence of the T cell receptor repertoire as compared to antigen processing-presentation in the selection of myelin basic protein epitopes in multiple sclerosis. 126
Charcot-Marie-Tooth (CMT) 1a duplication at 17p11.2 in Italian families. 126
Phenotypic and functional characterisation of CCR7+ and CCR7- CD4+ memory T cells homing to the joints in juvenile idiopathic arthritis. 126
A RCT Comparing Specific Intensive Cognitive Training to Aspecific Psychological Intervention in RRMS: The SMICT Study 126
Reciprocal interactions between human mesenchymal stem cells and gammadelta T cells or invariant natural killer T cells. 124
Mesenchymal stem cells shape microglia effector functions through the release of CX3CL1 123
Mesenchymal stem cells for multiple sclerosis: does neural differentiation really matter? 123
Acute desipramine restores presynaptic cortical defects in murine experimental autoimmune encephalomyelitis by suppressing central CCL5 overproduction. 122
NG2, a common denominator for neuroinflammation, blood-brain barrier alteration, and oligodendrocyte precursor response in EAE, plays a role in dendritic cell activation 122
Autologous haematopoietic stem-cell transplantation in multiple sclerosis: benefits and risks 121
X-Ray Phase Contrast Tomography Reveals Early Vascular Alterations and Neuronal Loss in a Multiple Sclerosis Model 121
Autologous stem cell transplantation for severe autoimmune diseases: a 10-year experience. 120
Primary varicella zoster infection associated with fingolimod treatment. 119
Cingulum bundle alterations underlie subjective fatigue in multiple sclerosis 119
Dysregulation of regulatory CD56bright NK cells/T cells interactions in multiple sclerosis 119
Intrathecal soluble HLA-E correlates with disease activity in patients with multiple sclerosis and may cooperate with soluble HLA-G in the resolution of neuroinflammation. 118
The therapeutic effect of mesenchymal stem cell transplantation in experimental autoimmune encephalomyelitis is mediated by peripheral and central mechanisms 118
The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. 118
Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells. 117
Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: A MRI-based clinical study. 116
Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. 116
T-cell trafficking in the central nervous system. 116
Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. 116
Delivery to the central nervous system of a nonreplicative herpes simplex type 1 vector engineered with the interleukin 4 gene protects rhesus monkeys from hyperacute autoimmune encephalomyelitis. 115
Relationship between retinal inner nuclear layer, age, and disease activity in progressive MS 115
Interindividual variability of cranioencephalic relationships as predicted by CT. 114
Costs and quality of life of multiple sclerosis in Italy. 114
Stem cells in inflammatory demyelinating disorders: a dual role for immunosuppression and neuroprotection. 114
Neuroprotective mesenchymal stem cells are endowed with a potent antioxidant effect in vivo. 114
Central and peripheral nervous system complications following allogeneic bone marrow transplantation. 114
Anti-Glutamic Acid Decarboxylase Limbic Encephalitis Without Epilepsy Evolving Into Dementia With Cerebellar Ataxia 114
Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS 113
Characterization of mouse spinal cord vascular network by means of synchrotron radiation X-ray phase contrast tomography 113
Systemic administration of mesenchymal stem cells increases neuron survival after global cerebral ischemia in vivo (2VO). 113
Induction of experimental autoimmune encephalomyelitis in rats and immune response to myelin basic protein in lipid-bound form. 113
Teriflunomide treatment reduces B cells in patients with MS. 112
Myelin basic protein intramolecular spreading without disease progression in a patient with multiple sclerosis. 112
Intravenous immunoglobulin, plasmalymphocytapheresis and azathioprine in chronic progressive multiple sclerosis. 111
Clinical baseline factors predict response to natalizumab: their usefulness in patient selection. 111
Demyelination and axonal damage in a non-human primate model of multiple sclerosis. 110
Surrogate endpoints for EDSS worsening in multiple sclerosis. A meta-analytic approach. 110
Dramatic rebounds of MS during pregnancy following fingolimod withdrawal. 110
Recommendations for the management of urinary disorders in multiple sclerosis: a consensus of the Italian Multiple Sclerosis Study Group. 109
Unraveling the regulatory role of NK cells on T-cell effector functions: Implications for CNS autoimmunity 109
Reward responsiveness and fatigue in multiple sclerosis. 109
Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. 108
Totale 13.194
Salva come PNG Salva come JPEG
Categoria #
all - tutte 81.184
article - articoli 73.162
book - libri 326
conference - conferenze 5.193
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.503
Totale 162.368
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20207.214 0 212 277 517 674 891 1.219 606 724 1.127 719 248
2020/20212.373 169 199 233 221 147 200 149 230 193 291 169 172
2021/20223.469 107 213 319 457 152 193 143 755 174 317 118 521
2022/20233.468 329 292 41 362 558 581 21 221 593 37 362 71
2023/20242.393 110 246 70 274 181 405 239 158 126 72 147 365
2024/2025359 340 19 0 0 0 0 0 0 0 0 0 0
Totale 26.592